Zacks Investment Research on MSN
These 2 medical stocks could beat earnings: Why they should be on your radar
Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter. Life and ...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes.
What recent performance says about Novavax Novavax (NVAX) has been moving on the radar again, with shares showing a mix of ...
Changing guidance around COVID-19 vaccines, specifically, has been central to RFK Jr.'s run as health secretary. A judge just ...
Novavax (NVAX) closed at $9.62 in the latest trading session, marking a -1.23% move from the prior day. The stock exceeded ...
Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...
StockStory.org on MSN
Therapeutics stocks Q4 teardown: Moderna (NASDAQ:MRNA) vs the rest
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, ...
Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...
A federal court injunction put a check on Health Secretary Robert F. Kennedy Jr.'s rapid assault on U.S. vaccine ...
U.S. District Judge Brian Murphy in Boston sided with the American Academy of Pediatrics and other medical groups, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results